High-resolution mass spectrometry in toxicology: current status and future perspectives

This paper reviews high-resolution mass spectrometry (HRMS) approaches using time-of-flight or Orbitrap techniques for research and application in various toxicology fields, particularly in clinical toxicology and forensic toxicology published since 2013 and referenced in PubMed. In the introduction, an overview on applications of HRMS in various toxicology fields is given with reference to current review articles. Papers concerning HRMS in metabolism, screening, and quantification of pharmaceuticals, drugs of abuse, and toxins in human body samples are critically reviewed. Finally, a discussion on advantages as well as limitations and future perspectives of these methods is included.

[1]  M. Meyer,et al.  Contribution of human esterases to the metabolism of selected drugs of abuse. , 2015, Toxicology letters.

[2]  M. Thevis,et al.  Annual banned-substance review: analytical approaches in human sports drug testing. , 2012, Drug testing and analysis.

[3]  M. Meyer,et al.  Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. , 2016, Drug testing and analysis.

[4]  J. Znaleziona,et al.  Determination and identification of synthetic cannabinoids and their metabolites in different matrices by modern analytical techniques - a review. , 2015, Analytica chimica acta.

[5]  Frederick G. Strathmann,et al.  A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. , 2015, American journal of clinical pathology.

[6]  M. Huestis,et al.  Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. , 2016, Rapid communications in mass spectrometry : RCM.

[7]  M. Meyer,et al.  Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. , 2014, Toxicology letters.

[8]  S. Johansen,et al.  Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-performance liquid chromatography with TOF-MS with data-independent acquisition. , 2013, Journal of separation science.

[9]  Ruedi Aebersold,et al.  Using data‐independent, high‐resolution mass spectrometry in protein biomarker research: Perspectives and clinical applications , 2015, Proteomics. Clinical applications.

[10]  Folker Westphal,et al.  The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.). , 2014, Drug testing and analysis.

[11]  Markus R Meyer,et al.  Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. , 2016, Bioanalysis.

[12]  H. Maurer Demands on scientific studies in clinical toxicology. , 2007, Forensic science international.

[13]  B. Shen,et al.  Rapid screening of drugs of abuse in human urine by high-performance liquid chromatography coupled with high resolution and high mass accuracy hybrid linear ion trap-Orbitrap mass spectrometry. , 2013, Journal of chromatography. A.

[14]  Bruno Domon,et al.  Advances in high‐resolution accurate mass spectrometry application to targeted proteomics , 2015, Proteomics.

[15]  M. Meyer,et al.  In vitro approaches to studying the metabolism of new psychoactive compounds. , 2011, Drug testing and analysis.

[16]  Emma K. Farrell,et al.  Biosynthesis, degradation and pharmacological importance of the fatty acid amides. , 2008, Drug discovery today.

[17]  H. Neels,et al.  Advances in detection of antipsychotics in biological matrices. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[18]  I. Zamora,et al.  Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. , 2016, Rapid communications in mass spectrometry : RCM.

[19]  C. J. Schmitt,et al.  Validated electrospray liquid chromatographic–mass spectrometric assay for the determination of the mushroom toxins α- and β-amanitin in urine after immunoaffinity extraction , 2000 .

[20]  Kayla N. Ellefsen,et al.  4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry , 2015, Forensic Toxicology.

[21]  M. Yarmush,et al.  Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions. , 2016, Tissue engineering. Part B, Reviews.

[22]  Wilhelm Schänzer,et al.  Annual banned-substance review: analytical approaches in human sports drug testing. , 2010, Drug testing and analysis.

[23]  M. Meyer,et al.  Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MSn, and LC-high-resolution-MSn , 2014, Analytical and Bioanalytical Chemistry.

[24]  M. Meyer,et al.  Direct analysis of the mushroom poisons α- and β-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatography-high resolution-mass spectrometry/mass spectrometry. , 2014, Journal of chromatography. A.

[25]  Herbert Oberacher,et al.  Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.

[26]  G. Lawson,et al.  Bisoprolol, ramipril and simvastatin determination in dried blood spot samples using LC-HRMS for assessing medication adherence. , 2013, Journal of pharmaceutical and biomedical analysis.

[27]  C. Kuo,et al.  Screening and confirmation of 62 drugs of abuse and metabolites in urine by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. , 2013, Journal of analytical toxicology.

[28]  Mingshe Zhu,et al.  Applications of mass spectrometry in drug metabolism: 50 years of progress* , 2015, Drug metabolism reviews.

[29]  C. Erratico,et al.  Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs. , 2015, Journal of pharmaceutical and biomedical analysis.

[30]  M. Castaneto,et al.  Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices , 2015, Drug metabolism reviews.

[31]  M. Huestis,et al.  Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.

[32]  M. Meyer,et al.  Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS. , 2014, Drug testing and analysis.

[33]  M. Meyer,et al.  Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n). , 2013, Journal of mass spectrometry : JMS.

[34]  Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. , 2015, Toxicology letters.

[35]  V. Gökmen,et al.  Future perspectives in Orbitrap™-high-resolution mass spectrometry in food analysis: a review , 2015, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[36]  Kurt R. Lehner,et al.  Linear pharmacokinetics of 3,4‐methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects , 2016, Addiction biology.

[37]  Nandkishor S. Chindarkar,et al.  Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening. , 2014, Clinical chemistry.

[38]  Shuguang Ma,et al.  Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. , 2013, Bioanalysis.

[39]  M. Huestis,et al.  High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. , 2016, Clinical chemistry.

[40]  T. Croley,et al.  Non-targeted screening approaches for contaminants and adulterants in food using liquid chromatography hyphenated to high resolution mass spectrometry. , 2016, Journal of chromatography. A.

[41]  M. Meyer,et al.  Dimethocaine, a synthetic cocaine derivative: studies on its in vitro metabolism catalyzed by P450s and NAT2. , 2014, Toxicology letters.

[42]  Mingshe Zhu,et al.  Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA , 2015, The AAPS Journal.

[43]  Frank T Peters,et al.  Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[44]  H. Maurer,et al.  Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[45]  M. Kettner,et al.  Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans? , 2017, Drug testing and analysis.

[46]  M. Meyer,et al.  2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques , 2013, Analytical and Bioanalytical Chemistry.

[47]  A. Wu,et al.  Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening. , 2016, Clinical chemistry.

[48]  L. Couchman,et al.  Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry , 2014, Therapeutic drug monitoring.

[49]  M. Huestis,et al.  Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. , 2011, Journal of mass spectrometry : JMS.

[50]  M. Meyer,et al.  In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach , 2016, Archives of Toxicology.

[51]  Kayla N. Ellefsen,et al.  In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. , 2016, Bioanalysis.

[52]  M. Burnier,et al.  Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis , 2015, Clinical Research in Cardiology.

[53]  M. Meyer,et al.  Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. , 2010, Bioanalysis.

[54]  Kayla N. Ellefsen,et al.  Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry , 2013, Analytical and Bioanalytical Chemistry.

[55]  H. Maurer,et al.  New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[56]  Mingshe Zhu,et al.  First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry , 2013, The AAPS Journal.

[57]  M. Meyer,et al.  Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn , 2013, Analytical and Bioanalytical Chemistry.

[58]  Adrian Covaci,et al.  A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples , 2015, Analytical and Bioanalytical Chemistry.

[59]  M. Ericsson,et al.  Methods for urine drug testing using one-step dilution and direct injection in combination with LC-MS/MS and LC-HRMS. , 2014, Bioanalysis.

[60]  M. Meyer New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics , 2016, Archives of Toxicology.

[61]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[62]  M. Meyer,et al.  Toxicokinetics of novel psychoactive substances: characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. , 2014, Toxicology letters.

[63]  M. Meyer,et al.  Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. , 2016, Toxicology letters.

[64]  GC-MS and LC-(high-resolution)-MSn studies on the metabolic fate and detectability of camfetamine in rat urine , 2014, Analytical and Bioanalytical Chemistry.

[65]  M. Meyer,et al.  Current position of high-resolution MS for drug quantification in clinical & forensic toxicology. , 2014, Bioanalysis.

[66]  Mingshe Zhu,et al.  Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. , 2014, Bioanalysis.

[67]  Robert Kronstrand,et al.  In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22 , 2016, The AAPS Journal.

[68]  M. Meyer,et al.  Studies on the metabolism and detectability of the designer drug β-naphyrone in rat urine using GC-MS and LC-HR-MS/MS. , 2013, Drug testing and analysis.

[69]  S. Fu,et al.  Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry. , 2015, Journal of analytical toxicology.

[70]  M. Meyer,et al.  Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches , 2016, Analytical and Bioanalytical Chemistry.

[71]  Marten Hanura,et al.  UPAYA UNITED NATIONS OFFICE ON DRUGS AND CRIME (UNODC) DALAM MENANGANI DRUG TRAFFICKING DI AFGHANISTAN PERIODE 2012-2013 , 2015 .

[72]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[73]  C. Junot,et al.  Multiplex quantification of protein toxins in human biofluids and food matrices using immunoextraction and high-resolution targeted mass spectrometry. , 2015, Analytical chemistry.

[74]  Odd Hordvin,et al.  The Drug Situation in Norway 2011 : Annual report to the European Monitoring Centre for Drugs and Drug Addiction - EMCDDA , 2009 .

[75]  M. Thevis,et al.  Human sports drug testing by mass spectrometry. , 2017, Mass spectrometry reviews.

[76]  Myron S. Cohen,et al.  The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[77]  Thomas Kraemer,et al.  Liquid chromatography, in combination with a quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic toxicology and comparison with informatio , 2014, Analytical chemistry.

[78]  M. Meyer,et al.  Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. , 2013, Biochemical pharmacology.

[79]  R. Gerona,et al.  Non-targeted screening for novel psychoactive substances among agitated emergency department patients , 2016, Clinical toxicology.

[80]  Ilkka Ojanperä,et al.  A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine , 2013, Analytical and Bioanalytical Chemistry.

[81]  P. Thai,et al.  Critical review on the stability of illicit drugs in sewers and wastewater samples. , 2016, Water research.

[82]  A. Eschalier,et al.  Fully automated semi-quantitative toxicological screening in three biological matrices using turbulent flow chromatography/high resolution mass spectrometry. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[83]  Mingshe Zhu,et al.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. , 2016, Drug testing and analysis.

[84]  Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn , 2014, Analytical and Bioanalytical Chemistry.

[85]  H. Maurer,et al.  Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn. , 2016, Drug testing and analysis.

[86]  S. Ferrara,et al.  Monitoring Haloperidol Exposure in Body Fluids and Hair of Children by Liquid Chromatography–High-Resolution Mass Spectrometry , 2013, Therapeutic drug monitoring.

[87]  Marilyn A Huestis,et al.  First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. , 2013, Clinical chemistry.

[88]  K. Johnson-Davis,et al.  Comparison of drug detection by three quadrupole time-of-flight mass spectrometry platforms. , 2015, Journal of analytical toxicology.

[89]  J. Tomková,et al.  Simultaneous determination of mushroom toxins α-amanitin, β-amanitin and muscarine in human urine by solid-phase extraction and ultra-high-performance liquid chromatography coupled with ultra-high-resolution TOF mass spectrometry. , 2015, Forensic science international.

[90]  R. Kronstrand,et al.  LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine , 2014, Analytical and Bioanalytical Chemistry.

[91]  M. Meyer,et al.  Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography–linear ion-trap (high-resolution) mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.

[92]  D. Boels,et al.  Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. , 2015, Drug testing and analysis.

[93]  M. Meyer,et al.  Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). , 2015, Journal of mass spectrometry : JMS.

[94]  L. Fanton,et al.  A validated method for quantifying atractyloside and carboxyatractyloside in blood by HPLC-HRMS/MS, a non-fatal case of intoxication with Atractylis gummifera L. , 2014, Journal of analytical toxicology.

[95]  M. Meyer,et al.  Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS. , 2013, Journal of mass spectrometry : JMS.

[96]  Anna T. Kelly,et al.  Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. , 2013, Journal of analytical toxicology.

[97]  A. DeCaprio,et al.  Covalent thiol adducts arising from reactive intermediates of cocaine biotransformation. , 2013, Chemical research in toxicology.

[98]  M. Meyer,et al.  Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs. , 2015, Analytica chimica acta.

[99]  I. Morel,et al.  Amatoxins (α- and β-Amanitin) and phallotoxin (Phalloidin) analyses in urines using high-resolution accurate mass LC-MS technology. , 2014, Journal of analytical toxicology.

[100]  H. Maurer,et al.  Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS , 2015, Analytical and Bioanalytical Chemistry.

[101]  Mingshe Zhu,et al.  High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. , 2015, Drug testing and analysis.

[102]  H. Maurer,et al.  New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems , 2016, Therapeutic drug monitoring.

[103]  M. Meyer,et al.  Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents , 2011, Analytical and Bioanalytical Chemistry.

[104]  F. Peters,et al.  Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis. , 2009, Journal of analytical toxicology.

[105]  Irene van den Broek,et al.  Current trends in mass spectrometry of peptides and proteins: Application to veterinary and sports-doping control. , 2015, Mass spectrometry reviews.

[106]  M. Meyer,et al.  Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MSn, and LC–HR–MS–MS , 2015, Analytical and Bioanalytical Chemistry.

[107]  H. Nakayama,et al.  High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS , 2015, International Journal of Legal Medicine.

[108]  F. Peters Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS. , 2014, Bioanalysis.

[109]  I. Dasgupta,et al.  A Novel 'Dilute-and-Shoot' Liquid Chromatography-Tandem Mass Spectrometry Method for the Screening of Antihypertensive Drugs in Urine. , 2015, Journal of analytical toxicology.

[110]  Mingshe Zhu,et al.  Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. , 2014, Bioanalysis.

[111]  M. Uder,et al.  Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation , 2016, Journal of the American Heart Association.

[112]  M. Meyer,et al.  Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail , 2014, Analytical and Bioanalytical Chemistry.

[113]  K. Linnet,et al.  Screening of 30 acidic and neutral pharmaceuticals in whole blood by fully automated SPE and UPLC-TOF-MS(E.). , 2013, Drug testing and analysis.

[114]  Marilyn A Huestis,et al.  Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. , 2015, Journal of chromatography. A.

[115]  M. Meyer,et al.  Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques , 2015, Analytical and Bioanalytical Chemistry.

[116]  Markus R Meyer,et al.  Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today? , 2016, Analytica chimica acta.

[117]  H. Maurer On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. , 1996, Therapeutic drug monitoring.

[118]  M. Meyer,et al.  Studies on the microbial biotransformation of the novel psychoactive substance methylenedioxypyrovalerone (MDPV) in wastewater by means of liquid chromatography-high resolution mass spectrometry/mass spectrometry. , 2014, The Science of the total environment.

[119]  Marilyn A Huestis,et al.  Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.

[120]  M. Meyer,et al.  Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MSn techniques , 2015, Analytical and Bioanalytical Chemistry.

[121]  Thomas Kraemer,et al.  Liquid chromatography, in combination with a quadrupole time-of-flight instrument, with sequential window acquisition of all theoretical fragment-ion spectra acquisition: validated quantification of 39 antidepressants in whole blood as part of a simultaneous screening and quantification procedure. , 2015, Analytical chemistry.

[122]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[123]  M. Meyer,et al.  Current applications of high-resolution mass spectrometry in drug metabolism studies , 2012, Analytical and Bioanalytical Chemistry.

[124]  H. Maurer,et al.  Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC–MS, LC–MSn, and LC–HR-MSn , 2013, Analytical and Bioanalytical Chemistry.

[125]  T. Tuzimski,et al.  Recent Trends in Sample Preparation and Liquid Chromatography/Mass Spectrometry for Pesticide Residue Analysis in Food and Related Matrixes. , 2015, Journal of AOAC International.

[126]  A. Pelander,et al.  Simultaneous identification and quantification of new psychoactive substances in blood by GC-APCI-QTOFMS coupled to nitrogen chemiluminescence detection without authentic reference standards , 2016, Analytical and Bioanalytical Chemistry.

[127]  Damià Barceló,et al.  Advances in liquid chromatography–high-resolution mass spectrometry for quantitative and qualitative environmental analysis , 2015, Analytical and Bioanalytical Chemistry.

[128]  M. Böhm,et al.  Witnessed drug intake before planned denervation--always harmless? , 2015, International journal of cardiology.

[129]  M. Meyer,et al.  Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS , 2015, Analytical and Bioanalytical Chemistry.